{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:02:34Z","timestamp":1790679754432,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.vaccine.2018.10.003","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T21:33:08Z","timestamp":1539207188000},"page":"6933-6943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The choice of analytical methodology can alter conclusions regarding herd effects of paediatric pneumococcal vaccination programmes"],"prefix":"10.1016","volume":"36","author":[{"given":"Jean-Yves","family":"Pir\u00e7on","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla A","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7704-0527","authenticated-orcid":false,"given":"Kaatje","family":"Bollaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-3960","authenticated-orcid":false,"given":"William P","family":"Hausdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5539-5319","authenticated-orcid":false,"given":"Christopher J","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.10.003_b0005","first-page":"129","article-title":"Pneumococcal vaccines WHO position paper - 2012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2018.10.003_b0010","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erv.12.53","article-title":"The fundamental link between pneumococcal carriage and disease","volume":"11","author":"Simell","year":"2012","journal-title":"Expert Rev Vacc"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.10.003_b0015","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1097\/INF.0000000000000083","article-title":"Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage","volume":"33","author":"Fleming-Dutra","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.10.003_b0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.vaccine.2013.05.005","article-title":"Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects","volume":"32","author":"Davis","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.003_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2018.10.003_b0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/INF.0b013e31824de9f6","article-title":"The worldwide impact of the seven-valent pneumococcal conjugate vaccine","volume":"31","author":"Fitzwater","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.10.003_b0035","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2214-109X(16)30306-0","article-title":"Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis","volume":"5","author":"Shiri","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2018.10.003_b0040","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2017.04.032","article-title":"Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature","volume":"35","author":"Tsaban","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.003_b0045","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.10.003_b0050","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.10.003_b0055","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1080\/21645515.2015.1052196","article-title":"Dissecting the indirect effects caused by vaccines into the basic elements","volume":"11","author":"Scarbrough Lefebvre","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.10.003_b0060","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"Serotype replacement in disease after pneumococcal vaccination","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.10.003_b0065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1023\/A:1007626510002","article-title":"Herd immunity and herd effect: new insights and definitions","volume":"16","author":"John","year":"2000","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.10.003_b0070","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/aje\/kwv283","article-title":"Relating pneumococcal carriage among children to disease rates among adults before and after the introduction of conjugate vaccines","volume":"183","author":"Weinberger","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.10.003_b0075","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/cid\/ciu524","article-title":"Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality","volume":"59","author":"Harboe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0080","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0090","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.vaccine.2017.03.031","article-title":"The herd effects of infant PCV7\/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel","volume":"35","author":"Regev-Yochay","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.003_b0095","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1016\/j.vaccine.2013.10.032","article-title":"Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway","volume":"31","author":"Steens","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.003_b0100","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0105","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1016\/j.vaccine.2013.07.006","article-title":"Vaccine effects and impact of vaccination programmes in post-licensure studies","volume":"31","author":"Hanquet","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.003_b0110","unstructured":"World Health Organization. Measuring impact of Streptococcus pneumoniae and Haemophilus influenzae type b conjugate vaccination, http:\/\/apps.who.int\/iris\/handle\/10665\/75835; 2012 [accessed 7 February 2018]."},{"key":"10.1016\/j.vaccine.2018.10.003_b0115","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/INF.0b013e3182787f89","article-title":"PCV13 impact evaluations: the obvious and the unpredicted","volume":"32","author":"O'Brien","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.10.003_b0120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/INF.0b013e31824bc1f0","article-title":"Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance","volume":"31","author":"Vergison","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.10.003_b0125","unstructured":"Australian Government Department of Health. Invasive pneumococcal disease in Australia, 2011 and 2012, http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/cda-cdi4002k.htm; [accessed 22 November 2017]."},{"key":"10.1016\/j.vaccine.2018.10.003_b0130","unstructured":"Australian Government Department of Health. National Notifiable Disease Surveillance System: Notifications of a selected disease by age group, sex and year; Pneumococcal disease (invasive), http:\/\/www9.health.gov.au\/cda\/source\/rpt_5_sel.cfm; 2001-2016 [accessed 1 February 2017]."},{"key":"10.1016\/j.vaccine.2018.10.003_b0135","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core (ABC) Surveillance Reports: Streptococcus pneumoniae, https:\/\/www.cdc.gov\/abcs\/reports-findings\/surv-reports.html; 1998-2014 [accessed July 2016]."},{"key":"10.1016\/j.vaccine.2018.10.003_b0140","unstructured":"Finnish National Institute for Health and Welfare (THL). Incidence of invasive pneumococcal disease in Finland, https:\/\/www.thl.fi\/en\/web\/thlfi-en\/research-and-expertwork\/projects-and-programmes\/monitoring-the-population-effectiveness-of-pneumococcal-conjugate-vaccination-in-the-finnish-national-vaccination-programme\/incidence-of-invasive-pneumococcal-disease-in-finland; 2016 [accessed 1 February 2017]."},{"key":"10.1016\/j.vaccine.2018.10.003_b0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.vaccine.2018.10.003_b0150","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial","volume":"381","author":"Palmu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.10.003_b0155","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1016\/j.vaccine.2017.05.089","article-title":"What is the heterogeneity in the impact seen with pneumococcal conjugate vaccines telling us?","volume":"35","author":"Hausdorff","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.003_b0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/594125","article-title":"Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997\u20132007","volume":"48","author":"Ardanuy","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0165","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1086\/323339","article-title":"Dynamics of penicillin-susceptible clones in invasive pneumococcal disease","volume":"184","author":"Henriques Normark","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/clinids\/15.1.99","article-title":"Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979\u20131990)","volume":"15","author":"Li\u00f1ares","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1473-3099(05)70083-9","article-title":"Epidemiological differences among pneumococcal serotypes","volume":"5","author":"Hausdorff","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0180","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/JCM.01538-13","article-title":"Serotype 5 pneumococci causing invasive pneumococcal disease outbreaks in Barcelona, Spain (1997 to 2011)","volume":"51","author":"Rolo","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.10.003_b0185","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1086\/591128","article-title":"Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population","volume":"47","author":"Romney","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0190","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/ciu366","article-title":"Outbreak of invasive Streptococcus pneumoniae serotype 12F among a marginalized inner-city population in Winnipeg, Canada, 2009\u20132011","volume":"59","author":"Schillberg","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0195","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1016\/j.vaccine.2011.02.016","article-title":"Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges","volume":"29","author":"Hanquet","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.003_b0200","doi-asserted-by":"crossref","first-page":"19868","DOI":"10.2807\/ese.16.20.19868-en","article-title":"Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales","volume":"16","author":"Flasche","year":"2011","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.10.003_b0205","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.vaccine.2015.01.030","article-title":"Early impact of PCV7\/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study","volume":"33","author":"Regev-Yochay","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.003_b0210","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.10.003_b0215","unstructured":"Australian Government Department of Health. The Australian Immunisation Handbook - Pneumococcal disease, http:\/\/www.immunise.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/Handbook10-home~handbook10part4~handbook10-4-13; [accessed 18 May 2018]."},{"key":"10.1016\/j.vaccine.2018.10.003_b0220","unstructured":"National Institute for Health and Welfare (THL). Pneumokokkipolysakkaridirokote eli PPV-rokote, https:\/\/thl.fi\/fi\/web\/rokottaminen\/rokotteet\/pneumokokkirokote\/pneumokokkipolysakkaridirokotukset-eli-ppv-rokotukset; [accessed 18 May 2018]."},{"key":"10.1016\/j.vaccine.2018.10.003_b0225","unstructured":"Public Health England. Pneumococcal: the green book, chapter 25, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/674074\/GB_Chapter_25_Pneumococcal_V7_0.pdf; [accessed 18 May 2018]."},{"key":"10.1016\/j.vaccine.2018.10.003_b0230","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.rmed.2011.07.008","article-title":"Pneumococcal vaccination in adults: does it really work?","volume":"105","author":"Pitsiou","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.vaccine.2018.10.003_b0235","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1473-3099(10)70318-2","article-title":"New approaches to the assessment of vaccine herd protection in clinical trials","volume":"11","author":"Clemens","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.003_b0240","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clinthera.2008.02.003","article-title":"The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine","volume":"30","author":"Isaacman","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2018.10.003_b0245","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.inf.0000222403.42974.8b","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects","volume":"25","author":"Ray","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.10.003_b0250","first-page":"343","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:28:21Z","timestamp":1759400901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18313550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":50,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0264410X18313550"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The choice of analytical methodology can alter conclusions regarding herd effects of paediatric pneumococcal vaccination programmes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}